Last updated: October 10, 2026
Amivantamab-vmjw, marketed as Rybrevant by Johnson & Johnson’s Janssen unit, has moved from a niche treatment for EGFR exon 20 insertion non-small cell lung cancer into a broader EGFR-directed franchise. Its commercial trajectory depends on three factors: expansion into common EGFR mutations, combination use with lazertinib and chemotherapy, and the durability of Johnson & Johnson’s biologic and patent protection.
Through mid-2024, Rybrevant had established a differentiated position in EGFR exon 20 insertion disease, but its financial upside remained tied to regulatory expansion. The drug’s most important commercial opportunity was first-line treatment with lazertinib for EGFR exon 19 deletion or L858R-positive advanced NSCLC, a materially larger population than the exon 20 insertion segment.
What is amivantamab-vmjw and how does it work?
Amivantamab-vmjw is a fully human, bispecific antibody directed against EGFR and MET. It binds both receptors, inhibits receptor signaling and promotes immune-mediated destruction of tumor cells through antibody-dependent cellular cytotoxicity.
The drug is administered intravenously. Its initial commercial limitations include infusion-related reactions, the need for repeated clinic visits, and combination-treatment complexity. These factors create a commercial disadvantage against oral EGFR tyrosine kinase inhibitors such as osimertinib and lazertinib, although the antibody’s activity in EGFR exon 20 insertion disease gives it a differentiated treatment role.
| Attribute |
Amivantamab-vmjw |
| Brand |
Rybrevant |
| Developer and marketer |
Janssen Biotech, Johnson & Johnson |
| Original developer |
Genmab |
| Drug class |
EGFR/MET bispecific antibody |
| Administration |
Intravenous infusion |
| Initial U.S. approval |
May 21, 2021 |
| Initial indication |
Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum chemotherapy |
| Primary commercial markets |
United States, Europe, Japan and other international markets |
| Main disease area |
EGFR-mutated non-small cell lung cancer |
The initial U.S. approval was accelerated and based on overall response rate and duration of response in platinum-pretreated EGFR exon 20 insertion NSCLC. The approval was supported by the CHRYSALIS study. Janssen later submitted confirmatory and expansion data supporting broader use in EGFR-mutated NSCLC (FDA, 2021).
How large is the amivantamab market opportunity?
The initial EGFR exon 20 insertion market is small but commercially attractive because the mutation has historically lacked effective targeted treatments. EGFR exon 20 insertions account for roughly 4% to 12% of EGFR mutations and approximately 1% to 2% of NSCLC cases, depending on the testing population and methodology.
The larger opportunity is the common EGFR-mutated population:
- EGFR exon 19 deletions and L858R mutations represent the majority of EGFR-positive NSCLC.
- These patients are typically treated with oral EGFR tyrosine kinase inhibitors, most prominently osimertinib.
- A first-line amivantamab-lazertinib regimen would position Rybrevant in a much larger treatment population.
- Combination treatment could increase revenue per patient but also raises toxicity, administration and reimbursement barriers.
The MARIPOSA phase 3 study evaluated amivantamab plus lazertinib against osimertinib in previously untreated EGFR-mutated advanced NSCLC. Johnson & Johnson reported that the combination reduced the risk of disease progression or death relative to osimertinib. The commercial value of this result depends on regulatory labeling, treatment duration, infusion logistics and physician willingness to replace an established oral standard of care (Johnson & Johnson, 2023).
What is the financial trajectory for Rybrevant?
Rybrevant’s sales have grown from a launch-stage product into a material oncology asset. Revenue has been driven by increasing diagnosis of EGFR exon 20 insertion disease, wider physician adoption, international launches and use in post-platinum treatment.
Johnson & Johnson has reported strong year-over-year growth for Rybrevant, although the product remained below blockbuster scale before potential first-line expansion. The sales pattern can be summarized as follows:
| Period |
Commercial status |
Financial implication |
| 2021 |
U.S. launch for post-platinum EGFR exon 20 insertion NSCLC |
Initial revenue base after May approval |
| 2022 |
Broader U.S. uptake and international rollout |
Growth from improved testing and specialist adoption |
| 2023 |
Increasing use in exon 20 insertion disease and preparation for label expansion |
Continued double-digit growth; product remained below the scale of mature J&J oncology franchises |
| 2024 onward |
Potential first-line combination with lazertinib and additional chemotherapy-based use |
Principal inflection point for revenue expansion |
J&J’s annual reports and quarterly filings should be used as the controlling source for precise product revenue because the company reports sales by brand and geography at different intervals. Publicly reported sales indicate that Rybrevant had reached several hundred million dollars in annual revenue by 2023, with a substantially higher trajectory expected if first-line combination use is approved and adopted (Johnson & Johnson, 2023, 2024).
The financial model has four major growth levers:
- More EGFR mutation testing and identification of exon 20 insertion patients.
- Treatment of patients after platinum chemotherapy.
- Use with chemotherapy after progression on osimertinib in common EGFR mutations.
- First-line use with lazertinib in exon 19 deletion or L858R disease.
The fourth lever is the most important. It would increase the addressable population by an order of magnitude compared with the original exon 20 insertion indication.
When does amivantamab lose regulatory exclusivity?
The first U.S. approval occurred on May 21, 2021. As a licensed biologic, amivantamab receives 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, subject to statutory rules governing the exclusivity calculation. The reference-product exclusivity period therefore extends into 2033, although the precise effective date for biosimilar approval and commercial entry depends on FDA determinations and litigation.
Biologic exclusivity does not eliminate patent risk. Johnson & Johnson may rely on:
- Composition-of-matter or antibody sequence patents.
- Binding-site and epitope patents.
- Bispecific antibody architecture patents.
- Formulation patents.
- Manufacturing and cell-line patents.
- Combination-treatment patents.
- Method-of-use patents covering specific EGFR mutations or treatment sequences.
A biosimilar applicant could challenge patents before the end of the 12-year biologic exclusivity period. Patent litigation under the Biologics Price Competition and Innovation Act could delay entry beyond the statutory exclusivity date.
What patents protect amivantamab-vmjw?
Amivantamab’s protection is expected to be distributed across a patent family rather than depend on a single product patent. Genmab and Janssen have historically used layered antibody protection for products developed through their collaboration.
The most commercially relevant categories are:
| Patent category |
Potential commercial coverage |
| Antibody composition |
Amivantamab amino-acid sequence and related variants |
| Target binding |
Binding to EGFR and MET epitopes |
| Bispecific format |
Dual-target antibody structure and architecture |
| Medical use |
Treatment of EGFR exon 20 insertion NSCLC |
| Combination therapy |
Amivantamab with lazertinib or platinum chemotherapy |
| Formulation |
Stable intravenous formulations and concentration ranges |
| Manufacturing |
Cell lines, expression systems and purification processes |
The patent position is stronger when composition claims cover the commercial antibody itself and weaker when protection rests mainly on narrow treatment regimens or manufacturing claims. Combination patents can remain commercially relevant after core antibody claims expire, but their value depends on label language and whether physicians use the patented regimen.
Amivantamab is not a small-molecule product listed in the FDA Orange Book in the same manner as a conventional tablet or capsule. Biologic patent and exclusivity analysis instead relies on the Purple Book, FDA biologic records, public patent databases and litigation filings.
What is the FDA regulatory status of amivantamab?
Rybrevant received accelerated FDA approval in 2021 for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease had progressed on or after platinum-based chemotherapy.
The regulatory pathway later expanded toward broader EGFR-mutated NSCLC:
- The MARIPOSA study supported first-line amivantamab plus lazertinib.
- MARIPOSA-2 evaluated amivantamab with chemotherapy in patients whose disease progressed after osimertinib.
- FDA review of supplemental applications was a major value driver during 2024.
- The product’s commercial profile depends on whether later approvals are traditional or accelerated and on the required confirmatory obligations.
The product’s regulatory advantage is the ability to address both a rare mutation-defined segment and, through combinations, the much larger common EGFR-mutated population.
How does amivantamab compare with competing EGFR drugs?
Amivantamab versus osimertinib
Osimertinib is an oral third-generation EGFR inhibitor and the established first-line standard for EGFR exon 19 deletion and L858R NSCLC. It is easier to administer and has broad physician familiarity.
Amivantamab’s advantages are its distinct mechanism, activity against EGFR exon 20 insertion disease and potential efficacy when used with lazertinib. Its disadvantages include intravenous administration, infusion reactions, rash, paronychia, treatment burden and combination toxicity.
Amivantamab versus mobocertinib
Mobocertinib was developed for EGFR exon 20 insertion NSCLC and competed directly with amivantamab. Its confirmatory trial did not establish the required benefit over chemotherapy. Takeda announced global withdrawal of Exkivity, and the U.S. product was withdrawn in 2024.
The withdrawal reduced direct competition in the exon 20 insertion market and strengthened Rybrevant’s position in that segment.
Amivantamab versus lazertinib
Lazertinib is an oral EGFR tyrosine kinase inhibitor. Its strategic importance is as a combination partner rather than a standalone competitor. The amivantamab-lazertinib regimen is intended to combine extracellular EGFR/MET blockade with intracellular EGFR inhibition.
The combination creates a larger commercial opportunity but also exposes Johnson & Johnson to competition from osimertinib monotherapy and other future combinations.
What generic, biosimilar and market-entry risks exist?
Traditional generic substitution is not the principal threat because amivantamab is a biologic antibody. The relevant competitor is a biosimilar or interchangeable biosimilar, subject to FDA requirements.
Near-term entry risk is limited by:
- The 12-year U.S. biologic exclusivity period.
- Potential composition and antibody patents.
- Manufacturing complexity.
- Specialized oncology distribution.
- The need for clinical confidence in biosimilar substitution.
- Potential patent litigation under the BPCIA.
Longer-term risks include biosimilar price erosion, label narrowing, loss of exclusivity for key combination regimens and improved oral therapies. A competing oral drug could reduce the value of Rybrevant even before biosimilar entry if it produces comparable outcomes with lower administration burden.
What licensing deal supports amivantamab?
Amivantamab originated from Genmab’s antibody platform and is commercialized by Janssen under a collaboration and license relationship. The agreement gives Janssen development and commercialization responsibilities while Genmab receives economic participation through royalties and other contractual payments.
The deal is commercially important because it gives Johnson & Johnson access to a differentiated bispecific antibody while allowing Genmab to participate in global sales without carrying the full cost of commercialization. Royalty obligations reduce Janssen’s net economics but do not materially change the product’s strategic value.
What litigation and settlement risks affect Rybrevant?
Through mid-2024, there was no widely reported biosimilar litigation or paragraph IV-style generic case comparable to small-molecule Orange Book litigation for Rybrevant. The principal future litigation risks are:
- BPCIA patent litigation initiated by a biosimilar applicant.
- Challenges to antibody composition claims.
- Challenges to formulation and manufacturing patents.
- Disputes over combination-treatment patents.
- Patent-term and regulatory-exclusivity disputes.
- Contract or royalty disputes involving Genmab.
Settlement agreements are unlikely to become commercially relevant until a biosimilar applicant files an application and identifies patents for challenge. No major public settlement governing U.S. biosimilar entry was established in the available record through mid-2024.
How strong is the amivantamab patent estate?
The estate is commercially strong in the near and medium term because biologic exclusivity, antibody manufacturing complexity and multiple potential patent layers operate together.
Its main weaknesses are structural:
- Patent protection may expire at different times across jurisdictions.
- Method-of-use claims can be narrower than composition claims.
- Combination patents may be difficult to enforce against off-label use.
- Biosimilar applicants can challenge patents before commercial entry.
- Oral EGFR inhibitors can create competitive pressure without infringing amivantamab patents.
The highest-value protection would be an enforceable composition claim covering the commercial antibody with an expiration date extending beyond the 2033 biologic-exclusivity period. Exact patent expiration analysis requires confirmation from current USPTO, FDA and court records.
What is the geographic coverage and international outlook?
Rybrevant has been commercialized in the United States and other major markets, including Europe and Japan. International growth depends on:
- Local approval of the exon 20 insertion indication.
- Reimbursement for high-cost intravenous oncology treatment.
- EGFR testing rates.
- Country-specific patent terms.
- Ability to obtain approval for combination regimens.
- Pricing controls and reference pricing.
The United States remains the most important market because of higher oncology drug prices and faster adoption of biomarker-defined therapies. Europe and Japan provide meaningful volume but generally impose greater pricing and health-technology-assessment pressure.
What generic launch scenarios should investors monitor?
Three scenarios define the commercial outlook.
| Scenario |
Driver |
Market impact |
| Base case |
Continued exon 20 insertion use and gradual combination adoption |
Sustained growth but limited by infusion burden |
| Upside case |
Broad first-line use with lazertinib and durable superiority over osimertinib |
Expansion toward blockbuster oncology revenue |
| Downside case |
Combination toxicity, reimbursement resistance or weak uptake against osimertinib |
Rybrevant remains a specialty product concentrated in exon 20 disease |
The most important operating indicators are new-start patient volume, duration of therapy, share of first-line EGFR prescriptions, infusion-reaction management, combination dosing, and gross-to-net pricing.
Key Takeaways
- Amivantamab-vmjw is a differentiated EGFR/MET bispecific antibody marketed as Rybrevant.
- Its original market was EGFR exon 20 insertion NSCLC after platinum chemotherapy.
- Its larger commercial opportunity is first-line EGFR-mutated NSCLC in combination with lazertinib.
- Mobocertinib’s withdrawal reduced direct competition in the exon 20 insertion segment.
- U.S. biologic exclusivity extends into 2033 based on the May 2021 first approval.
- Patent protection is likely layered across antibody composition, bispecific structure, formulation, manufacturing and treatment methods.
- The drug is not subject to conventional Orange Book generic substitution analysis.
- The largest commercial risks are intravenous administration, combination toxicity, osimertinib competition, reimbursement pressure and eventual biosimilar entry.
- Genmab’s licensing relationship gives it royalty economics while Janssen funds and manages commercialization.
- The first-line combination strategy determines whether Rybrevant remains a specialty oncology product or becomes a broader blockbuster franchise.
FAQs About Amivantamab-vmjw Market and Exclusivity
Is amivantamab-vmjw a blockbuster drug?
It had not reached mature blockbuster scale through mid-2024, but first-line combination use could materially expand revenue beyond the exon 20 insertion market.
Does amivantamab have a biosimilar?
No commercially available amivantamab biosimilar was established in the available record through mid-2024. Biosimilar entry is constrained by biologic exclusivity, patents and manufacturing complexity.
Is Rybrevant listed in the Orange Book?
Rybrevant is a biologic antibody and is not analyzed through the standard small-molecule Orange Book framework. The FDA Purple Book and patent litigation records are more relevant.
What drug competes most directly with Rybrevant?
Mobocertinib was the closest direct competitor in EGFR exon 20 insertion NSCLC, but its withdrawal reduced that competition. Osimertinib is the principal competitor in common EGFR-mutated NSCLC.
What could reduce Rybrevant sales before patent expiry?
Lower-than-expected uptake of amivantamab-lazertinib, infusion burden, treatment-related toxicity, payer restrictions, competing oral therapies and use of alternative EGFR combinations could reduce sales before biosimilar entry.
References
-
Food and Drug Administration. (2021). FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. U.S. Department of Health and Human Services.
-
Johnson & Johnson. (2023). 2023 annual report. Johnson & Johnson.
-
Johnson & Johnson. (2024). First-quarter 2024 financial results. Johnson & Johnson.
-
Johnson & Johnson. (2023). Johnson & Johnson announces results from the MARIPOSA study of amivantamab plus lazertinib in EGFR-mutated non-small cell lung cancer. Johnson & Johnson.
-
Genmab A/S. (2023). Annual report 2023. Genmab.
-
Takeda Pharmaceutical Company Limited. (2024). Exkivity global withdrawal information. Takeda Pharmaceutical Company Limited.